Novartis sold its listed India unit for ₹1,446 crore, finishing its pure-play pivot
With India-listed sales sliding from ₹655 to ₹493 crore after its heart drug lost patent, Novartis exited the listed unit — the stock jumped 20% on the news.
What was changed
In February 2026 Novartis AG agreed to sell its entire 70.68% stake in Mumbai-listed Novartis India for ₹1,446 crore to a consortium led by Indian private equity firm ChrysCapital, with WaveRise Investments and Two Infinity Partners also participating. The consortium simultaneously announced a mandatory open offer for up to a further 26% at Rs 860.64 per share, totalling about ₹552.50 crore.
The exit follows a strategic business review Novartis began in February 2024. Novartis India's 12-month sales had declined to ₹493 crore by end-December 2025 from ₹655 crore in December 2022, with Vymada — the biggest revenue contributor — falling to ₹180 crore from ₹258 crore after going off patent and facing generic competition.
Novartis framed the sale as completing 'its transformation into a pure-play innovative medicines company', adapting its footprint for efficient, sustainable long-term growth. The company stays in India through wholly owned Novartis Healthcare Pvt Ltd: the commercial arm, the Hyderabad corporate centre, R&D across more than 300 trial sites, and the largest pharma global capability centre in India, employing over 9,000 people — about 11% of its global workforce.
The market's verdict was immediate: Novartis India shares surged the daily 20% limit to close at Rs 996.5 on the BSE, against a 0.38% Sensex rise. The deal was expected to close in the September quarter of 2026, subject to conditions; its effect on Novartis India's 2022 in-licensing and distribution deal with Dr Reddy's Laboratories remained unclear.
Why it worked
The listed unit's economics had structurally deteriorated — sales down a quarter in three years as the lead drug lost exclusivity.
Selling the listed entity let Novartis keep full control of the parts that matter to its strategy: innovative medicines commercial operations, the Hyderabad GCC and clinical development.
It is the closing move of the pure-play refocus Novartis began years earlier, following moves such as the Alcon eye-care spin-off.
The consortium's open offer at Rs 860.64 gave minority shareholders an exit path, smoothing regulatory completion.
What can be applied
Exiting a market's listed vehicle is not exiting the market: keep the owned operations that fit the strategy and sell the entity whose economics no longer do.
Aftermath
Closing was expected in the September quarter of 2026 subject to conditions; Dr Reddy's said it was too early to comment on the fate of its distribution pact for Novartis's established brands, while Novartis continued expanding its Cardio Renal Metabolic and oncology portfolio in India.